1	Seroepidemiology of COVID-19 in pregnant
2	women and their infants in Uganda and Malawi
3	across multiple waves 2020-2022
4	
5	Lauren Hookham <sup>1,2*</sup> , Liberty Cantrell <sup>2</sup> , Stephen Cose <sup>3,4</sup> , Bridget Freyne <sup>5,6</sup> , Luis Gadama <sup>7</sup> ,
6	Esther Imede <sup>4</sup> , Kondwani Kawaza <sup>7</sup> , Samantha Lissauer <sup>5,6</sup> , Phillipa Musoke <sup>8</sup> , Vicki
7	Nankabirwa <sup>9</sup> , Musa Sekikubo <sup>10</sup> , Halvor Sommerfelt <sup>11,12</sup> , Merryn Voysey <sup>2</sup> , The periCOVID
8	Consortium <sup>^</sup> , Kirsty Le Doare <sup>1,13,</sup>
9	
10	1 Institute for Infection and Immunity, St George's, University of London, London, UK
11	2 Oxford Vaccine Group, Department of Paediatrics, University of Oxford
12	3 London School of Hygiene & Tropical Medicine
13	4 MRC/UVRI and LSHTM Uganda Research Unit
14	5 Malawi Liverpool Wellcome Trust
15	6 Institute of Infection, Veterinary and Ecological Science, University of Liverpool
16	7 Kamuzu University of Health Sciences: University of Malawi College of Medicine
17	8 Department of Paediatrics and Child Health, Makerere University
18	9 Department of Epidemiology & Biostatistics, School of Public Health, Makerere University
19	10 Department of Obstetrics & Gynaecology Makerere University
20	11 Centre for Intervention Science in Maternal and Child Health, Department of Global
21	Public Health and Primary Care, University of Bergen NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 22 12 Norwegian Institute of Public Health.
- 23 13 Makerere University, John's Hopkins University, Uganda

24

- 25 \* Corresponding author
- 26 E-mail: <u>lhookham@sgul.ac.uk</u>
- 27 ^Membership of the periCOVID Consortium is provided in the Acknowledgments.

29

## **30 Abstract**

31	Data on SARS-CoV-2 infection in pregnancy and infancy has accumulated throughout the
32	course of the pandemic. However, limited information is available from countries in sub-
33	Saharan Africa (SSA). Evidence regarding asymptomatic SARS-CoV-2 infection and adverse
34	birth outcomes are also scarce in these countries. The pregnant woman and infant COVID in
35	Africa study (PeriCOVID Africa) is a South-South-North partnership involving hospitals and
36	health centres in five countries: Malawi, Uganda, Mozambique, The Gambia, and Kenya. The
37	study leveraged data from three ongoing prospective cohort studies: Preparing for Group B
38	Streptococcal Vaccines (GBS PREPARE), SARS-CoV-2 infection and COVID-19 in women and
39	their infants in Kampala and Mukono (COMAC) and Pregnancy Care Integrating Translational
40	Science Everywhere (PRECISE). In this paper we describe the seroepidemiology of SARS-
41	CoV-2 infection in pregnant women enrolled in sites in Uganda and Malawi, and the impact
42	of SARS-CoV-2 infection on pregnancy and infant outcomes.
43	The PeriCOVID study is a prospective mother-infant cohort study that recruited pregnant
44	women at any gestation antenatally or on the day of delivery. A nasopharyngeal swab was
45	taken from mothers at enrolment for RT-PCR confirmation of SARS-CoV-2 infection, and
46	maternal and cord blood samples were tested for SARS-CoV-2 antibodies using Wantai and
47	Euroimmune ELISA. The primary outcome was seroprevalence of SARS-CoV-2 antibodies in
48	maternal blood, reported as the proportion of seropositive women by study site and wave
49	of COVID-19 within each country. Placental transfer of antibodies was described using the
50	geometric mean ratio (GMR). We also estimated the proportion of asymptomatic or
51	subclinical COVID-19 infections in pregnant women using serological testing and collected

adverse pregnancy and infancy outcomes (e.g. still-birth, prematurity, maternal or infantdeath).

54	In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant
55	women had a SARS-CoV-2 positive serology. Over subsequent waves (delta and omicron), in
56	the absence of vaccination, seropositivity rose from 20% to over 80%. The placental transfer
57	GMR was 1.7, indicating active placental transfer of anti-spike IgG. There was no association
58	between SARS-CoV-2 antibody positivity and adverse pregnancy or infancy outcomes.
59	This study describes the increasing prevalence of SARS CoV-2 antibodies in pregnant woman
60	in Uganda and Malawi across waves of SARS-CoV-2 infection. Our study adds to existing
61	evidence that suggests under-reporting of infection if based solely on cases with clinical
62	disease, or a positive RT-PCR for SARS-CoV-2, as most of the women in our study had
63	asymptomatic infections and did not seek medical care. This has implications for screening
64	in subsequent outbreaks and pandemics where protection of pregnant women and effect of
65	infection in pregnancy on the infant are unknown.

66

## 67 Introduction

68	The initial predictions of the impact of SARS-CoV-2 in sub-Saharan Africa suggested high
69	case numbers and fatalities (1), yet there is evidence to suggest that the pandemic evolved
70	differently in Africa than in other regions (2, 3). Several factors have been proposed to
71	explain the relatively low frequency of severe SARS-CoV-2 illness, including a younger
72	population, a lack of long-term care facilities and reduced population density (4-7).
73	However, limited testing capacity and weak reporting structures in many sub-Saharan
74	African countries may also result in under-reporting, leading to an underestimation of the
75	true risk of serious SARS-CoV-2 infection (3). Infection in pregnancy, even if asymptomatic or
76	mild, may have long-term impacts for a pregnant woman or impair the neurodevelopment
77	of her child, a risk which is well established for viral infections such as Zika virus or
78	cytomegalovirus (8).Data on the impact of SARS-CoV-2 infection in pregnancy on
79	neurodevelopmental outcomes is emerging (9, 10). Evidence regarding asymptomatic SARS-
80	CoV-2 infection and adverse birth outcomes is limited and the long-term effects of the
81	pandemic on infant health remain poorly understood (11).

82

Serological surveillance is a useful means of estimating population-level immunity against
infectious diseases using cross-sectional studies of antibody prevalence (12). In the case of
SARS-CoV-2, serological surveys are helpful in estimating the number of people who have
been exposed to SARS-CoV-2, whether they were symptomatic or not to better clarify the
dynamics of exposure during the different epidemic waves as vaccines were rolled out (13).
For example, seroprevalence surveys conducted across Kenya, South Africa and Malawi

have all reported community transmission, which is several times higher than that detected
by national virological surveillance programmes (14-16).

91

Seroprevalence studies in pregnancy enables insights into the real magnitude of exposure to 92 SARS-CoV-2 infections and the extent of under-reporting of SARS-CoV-2 cases. Information 93 on seroprevalence in pregnancy, placental antibody transfer and antibody half-life also offer 94 the possibility to approximate the number of mother-infant dyads who could potentially 95 96 exhibit immunological protection against subsequent infections, especially with low vaccine coverage in many low-resource settings (LRS). Finally, seroprevalence studies can also 97 provide insight into the relationship between infection and vaccination, symptoms, and 98 antibody responses to assist with future screening and prevention policies in pregnancy. 99 100 101 To address these specific gaps, we investigated the seroprevalence and the associations of 102 different factors on seropositivity to the SARS-CoV-2 virus among pregnant women and their infants in Uganda and Malawi. This was performed during consecutive SARS-CoV-2 waves. 103 104

### 105 Methods

### 106 Study design and participants

PeriCOVID Africa is a multi-site prospective mother-infant cohort study using an adapted
WHO UNITY protocol (17), whereby women were categorised into two categories
dependent on serological testing using the Wantai total antibody assay as exposed (positive
serology) or unexposed (negative serology) to SARS-CoV-2. Women were additionally
screened for symptoms, using the WHO definition for probable COVID-19 disease at the

time of study participation (18). We defined symptomatic COVID-19 infection according to
the WHO definitions of probable COVID-19 illness (18) and asymptomatic infection as
seropositive or PCR positive at enrolment in the absence of reported symptoms. Unexposed
women were those with no reported symptoms consistent with SARS-CoV-2 infection and
negative serology.

117

#### 118 Recruitment

- 119 Each study adapted the WHO UNITY protocol according to local needs and capacity
- 120 considerations. Women were recruited into the study either during an antenatal visit, or
- 121 during labour at seven study clinics and hospitals in Uganda and Malawi. In all studies,
- 122 gestational age at enrolment was estimated by date of last menstrual period and fundal
- 123 height. Additionally, in periCOVID Uganda and periCOVID Malawi Ballard scores were
- 124 calculated at birth. Individual study recruitment, sampling and follow up are shown in Table
- 125 1. The first participant was recruited 1<sup>st</sup> February 2021. Final participant follow and sampling

126 was concluded by 31<sup>st</sup> January 2022.

127

128 Table 1. Recruitment, sampling and follow-up by study site.

Study Site	Enrolment timing	Study period	Inclusion Criteria	Exclusion Criteria	Sampling at enrolment	Follow up
All sites			Willingness to provide informed consent		Maternal and Cord blood	6 week follow up
periCOVID Uganda	Antenatal clinic or delivery	February 2021 – January 2022	Pregnant women (including emancipated minors aged over 14 years) at any gestation including the day of delivery Planning to deliver at one of the designated study sites and willing to stay in the area for the first six weeks of their baby's life Willing to attend a follow up visit at six weeks postpartum	No exclusion criteria	Maternal nasopharyngeal swab*	For COVID-19 Cases only*. Maternal: nasopharyngeal maternal blood sample (5ml serum), Infant: nasal swab, blood sample (2-5ml) or dried blood spot,
COMAC	Delivery	August 2021 – January 2022	<ul> <li>low risk of infection with tuberculosis in the household</li> <li>mother of legal age (including if emancipated minor) for participation</li> <li>mother residing within the study area, not intending to move out</li> </ul>	<ul> <li>Baby weighs less than 2kg at birth</li> <li>Baby requires hospital admission for severe illness at birth</li> <li>Serious congenital malformation(s)</li> <li>severely ill mother on the day of giving birth whose condition(s)</li> </ul>	Nil additional	Maternal blood test at 14 weeks. Nasopharyngeal swab at 6 weeks and 14 weeks. Infant: blood test at 14 weeks. Nasopharyngeal swab at 6 weeks and 14 weeks

			of the area in the next 4 months and is likely to be traceable for up to 12 months. - HIV-1 positive women should be receiving the necessary antiretroviral treatment and prophylaxis (Ugandan Option B+ guidelines) HIV-exposed babies receives peri exposure prophylaxis (Ugandan Option B+ guidelines)	require(s) hospitalization -		
Malawi	Delivery	March 2021 – January 2022	All women presenting to QECH in labour with an estimated gestation of 28 weeks or greater who - Are willing to attend a follow up visit at 6 weeks postpartum	No exclusion criteria.	Nil additional	For COVID-19 cases only. Maternal *blood, rectal swab, breastmilk. Infant*: blood

131

#### 132 COVID-19 testing

- 133 All women at all study sites were screened for COVID-19 symptoms using a standardised
- data collection form with questions including a recent history of fever, cough, anosmia and
- ageusia and contact with a known SARS-Cov-2 case. Information on COVID-19 illness
- 136 symptoms was collected at enrolment for the 14 days prior to enrolment in PeriCOVID
- 137 Uganda and Malawi, and in the 28 days prior to enrolment in COMAC Uganda. Women
- 138 enrolled in PeriCOVID Uganda had a nasal swab taken at enrolment to test for SARS-CoV-2
- 139 by PCR. In Malawi throat swabs were taken if the clinical syndrome was suggestive of a
- 140 probable COVID-19 illness as defined by the WHO (18).

#### 141 Blood sampling

142 Sampling at all sites for antibodies to SARS-COV-2 included at least a maternal venous and

143 paired cord blood sample (see Table 1 for sampling schedule at each site).

#### 144 Data collection

Each site (KNRH, Kawaala, Kitebi or Mukono General Hospital in Kampala, Uganda and QECH 145 in Blantyre, Malawi) used a study questionnaire which was completed by research staff to 146 capture information from study participants and then uploaded to a central RedCAP 147 database. This included data on maternal age, significant past medical history, HIV and 148 149 socioeconomic status; onset and duration of signs and symptoms of SARS-CoV-2 illness if 150 present, and self-reporting of prior SARS-CoV-2 illness; gestational age at enrolment, parity, number of foetuses (if known before delivery), co-infection with malaria, vaccinations 151 received in pregnancy including the SARS-CoV-2 vaccines; gestational age at delivery, 152 153 delivery method, intrapartum and postpartum complications such as pre-term birth,

stillbirth, abortion, and maternal death; neonatal outcomes including evidence of COVID-19
illness, Neonatal Intensive Care Unit (NICU) admission, low birth weight and neonatal death;
infant health status

157

### 158 Laboratory methods

As per FIND guidelines at the time of the study protocol development (19), we used three 159 different SARS-CoV-2 specific antibody assays that targeted either the receptor binding 160 domain (RBD; total antibody), the spike protein (anti-S, total antibody) or nuclear capsid 161 (anti-NCP, IgG). We performed in-house specificity and sensitivity testing, respectively, using 162 100 pre-COVID19 (pre-2019) samples selected by month for seasonality assessment and 20 163 164 PCR positive samples (19) to perform assay validation. We also examined potential crossreactivity in our assay from malaria-specific antibodies using 74 women who tested positive 165 166 to malaria (antibody positive by rapid diagnostic test (RDT) from pre-COVID samples and 15 SARS-COV-2 PCR positive samples in women who did not have malaria (negative RDT) during 167 the COVID-19 pandemic. Results can be seen in Supplementary Table S1. 168 169

170 Laboratory analysis

Laboratory testing for SARS-COV-2 antibodies was performed at the MRC/UVRI and LSHTM Uganda Research Unit or the Malawi Liverpool Wellcome facilities using the Wantai SARS-CoV-2 total antibody ELISA kit (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Beijing, China). The manufacturer-reported assay sensitivity is 94.4%, with a specificity of 100%. All specimens that tested positive for Wantai were tested using Euroimmun Anti-SARS-CoV-2 NCP/S ELISA (IgG) (Euroimmun, Lübeck, Germany) kits for the detection of IgG antibodies to

SARS-COV-2 nucleocapsid and spike (S1 and S2) proteins, respectively. Euroimmun Anti-SARS-177 CoV-2 NCP/S ELISA (IgG) is a semi-guantitative immunoassay with a reported sensitivity of 178 94.6% and specificity of 99.8% in samples collected at least 10 days after confirmed SARS-179 COV-2 infection. A sample was considered positive if the Wantai test was positive. Results 180 which were reported as borderline on the Euroinmmune assay were considered as negative 181 for the purpose of our analysis. Due to variable specificity of the Euroimmune assay, we report 182 Wantai results for all outcomes as per manufacturer's instructions. 183 184 As the Wantai ELISA is a qualitative test, WHO standards for NCP and S proteins were run on all assays. The stock concentration for NCP and S proteins was 123µg/ml and 1000µg/ml, 185 respectively. The working concentration for both NCP and S proteins was 2  $\mu$ g/ml. The 186 187 calibration curve was created using WHO International standard for anti-SARS-CoV-2 188 immunoglobulin (NIBSC 20/136) using a 12-well dilution series created in 1.75-fold steps, starting at 1:200 and this series was used to generate the curve. All laboratory testing in 189 190 Uganda for SARS-CoV-2 antibodies was performed using the ETI-MAX 3000 (Diasorin, 191 Saluggia, Italy).

192

#### **Data Analysis**

Although there was no predefined sample size, we aimed to obtain samples from at least 1000 women and infants across all sites. The sero-epidemiological analyses were carried out using all participants with enrolment blood sample results available for analysis. The proportion of seropositive results was calculated for the individual waves of SARS-CoV-2 within each country. This was done for maternal blood samples to estimate the seroprevalence of SARS-CoV-2 among pregnant women, and for cord blood samples to

200	estimate the seroprevalence of SARS-CoV-2 antibodies in infants. The dates used to define
201	the SARS-COV-2 waves in each country are given in Table S2 and were taken from Our World
202	in Data $(20)$ . Waves were defined by taking the nadir between each peak for the start and
203	end dates of each wave. Confidence intervals for prevalence estimates were computed
204	using the Clopper-Pearson (Binomial Exact) method.
205	
206	The geometric mean concentration (GMC) and 95% confidence intervals (CI) of anti-S and
207	anti-NCP antibodies measured on the Euroimmune assay were calculated for mother-infant
208	pairs. To study the rate of placental transfer of SARS-CoV-2 antibodies, the geometric mean
209	ratio (GMR) of infant to maternal antibodies was calculated.
210	
211	The proportion of participants with a symptomatic or asymptomatic infection was
212	calculated for women who were seropositive at enrolment and for those who had a positive
213	RT-PCR test at enrolment.
214	
215	The impact of infection on key pregnancy and neonatal outcomes was modelled for women
216	and infants in PeriCOVID Malawi and Uganda log-binomial generalised linear models (GLM)
217	which were adjusted for country. Models were constructed for maternal death, infant
218	death, combined adverse pregnancy outcome (at least one of maternal death, abortion,
219	premature labour or stillbirth), and the combined adverse neonatal outcome (at least one of
220	neonatal/infant death, prematurity, low birth weight, NICU admission after birth, or birth
221	asphyxia). Relative risks were presented with 95% confidence intervals for all models
222	reaching convergence. Results were not presented for adverse outcomes with fewer than 5
223	events.

224

- 225 Statistical analyses were carried out using R version 4.2.1. No significance tests were
- 226 conducted.

227

## 228 Ethical Considerations

- 229 The study documents were reviewed and approved by the Ethics Committee of the relevant
- 230 institutions: Uganda: Makarere University School of Medicine (SOMREC), Uganda National
- 231 Council for Science and Technology (UNCST); Regional Committees for Medical and
- 232 Research Ethics in Norway; Malawi: College of Medicine Research Ethics Committee
- 233 (COMREC).

234

235

## 236 **Results**

- 237 In total, 1379 women were enrolled, giving birth to 1387 infants (Fig 1, Table 2). The mean
- age of all women was 26 years (SD 6) across the three sites. Most (n=1346, 98%)
- pregnancies were singleton. The HIV prevalence was 9% (n= 272). 371 women delivered
- outside of a study hospital and so no blood samples were available for analysis. Deliveries of
- 1024 infants with cord blood samples occurred at study sites. Almost all were livebirths
- 242 (n=1009/1024, 99%) and most (n=888/1024, 87%) were not admitted to the NICU after birth
- 243 (Table 2). A total of 909/1379 (65.9%) women in periCOVID Uganda and periCOVID Malawi
- had a PCR result at enrolment available for analysis of which 68/909 (7.5%) women had
- positive PCR results for SARS-CoV-2. Amongst these women, 77.9% (n=53) had symptoms
- consistent with COVID-19 disease. The majority (88.7%, n=47/53) were in Malawi who were

- 247 performing RT-PCR testing only on symptomatic women. In periCOVID Uganda, where all
- 248 women had a RT-PCR test at enrolment, 31.6% (n=6/19) of those with a positive RT-PCR test
- had symptoms suggestive of COVID-19 disease (Supplemental Table 3). Genotyping revealed
- all positive cases from Uganda to be of the delta variant.
- 251
- 252
- 253 Fig 1. Study flow chart. Study flow chart to show the number of women enrolled by study,
- with maternal serology available at enrolment (maternal result) and the infants with cordblood serology (cord blood result) available.
- 256

#### **Table 2. Demographics for women and infants in the study.**

Characteristic of women enrolled	Overall, N = 1,379	PeriCOVID Malawi, N = 387	PeriCOVID Uganda, N = 836	COMAC Uganda, N = 156
Age (years)	26 (6)	25 (7)	26 (6)	27 (5)
Missing	2	2	0	0
Number of fetuses				
Singleton	1,346 (98%)	371 (96%)	819 (98%)	156 (100%)
Twins	30 (2.2%)	14 (3.6%)	16 (1.9%)	0 (0%)
Triplets	1 (<0.1%)	0 (0%)	1 (0.1%)	0 (0%)
Missing	2	2	0	0
Highest level of education				
Graduate Education /Terminal Degree Completed.	23 (1.7%)	1 (0.3%)	20 (2.4%)	2 (1.3%)
No Formal Education	12 (0.9%)	5 (1.3%)	5 (0.6%)	2 (1.3%)
Other	2 (0.1%)	0 (0%)	2 (0.2%)	0 (0%)
Primary Education Completed	211 (15%)	98 (26%)	84 (10%)	29 (19%)
Secondary Education Completed	252 (18%)	129 (34%)	105 (13%)	18 (12%)

Some Primary Education	239 (17%)	126 (33%)	86 (10%)	27 (17%)
Some Secondary Education	509 (37%)	0 (0%)	432 (52%)	77 (49%)
University / College Completed	127 (9.2%)	25 (6.5%)	101 (12%)	1 (0.6%)
Missing	4	3	1	0
HIV				
No	1,107 (91%)	325 (84%)	782 (94%)	0 (NA%)
Yes	114 (9.3%)	60 (16%)	54 (6.5%)	0 (NA%)
Missing	158	2	0	156
Characteristics of infants born and providing a cord blood sample	Overall, N = 1,024	PeriCOVID Malawi, N = 365	PeriCOVID Uganda, N = 503	COMAC Uganda, N = 156
Status of infant at birth				
Livebirth	1,009 (99%)	357 (99%)	496 (99%)	156 (100%)*
Miscarriage	2 (0.2%)	1 (0.3%)	1 (0.2%)	0 (0%)
Stillbirth	10 (1.0%)	4 (1.1%)	6 (1.2%)	0 (0%)
Missing	3	3	0	0
Gestation at birth (weeks)	27, 44	27, 44	28, 44	Inf, -Inf
Missing	157	1	0	156

Sex				
Female	492 (48%)	164 (45%)	248 (49%)	80 (51%)
Male	531 (52%)	200 (55%)	255 (51%)	76 (49%)
Missing	1	1	0	0
Birth weight (grams)				
Mean (SD)	3,082 (540)	2,910 (573)	3,151 (504)	3,262 (458)
Range	600, 4,850	600, 4,500	1,200, 4,850	2,100, 4,700
Missing	8	2	6	0
Admitted to NICU after birth				
No	888 (87%)	264 (73%)	468 (93%)	156 (100%)*
Yes	133 (13%)	98 (27%)	35 (7.0%)	0 (0%)
Missing	3	3	0	0
	1	1		

9 \* COMAC Uganda only recruited infants who were born alive and not admitted to the NICU after birth

#### 260

261

### 262 Seropositivity in pregnant women and their infants

- 263 Overall, 1371/1379 maternal samples (382 from Malawi and 989 from Uganda) and
- 264 987/1024 cord blood samples (359 from Malawi and 628 from Uganda) were available for
- analysis (Table 3 and 4). There were 875 SARS-CoV-2 seropositive women in the study (257
- in Malawi, 618 in Uganda), of whom 791 (90.4%) were asymptomatic in the 14 days
- 267 (periCOVID Uganda and Malawi) -28 days (COMAC) prior to enrolment. This corresponded in
- 268 Malawi to 21 asymptomatic seropositive participants during the second wave, 134 during
- the third wave and 57 in the fourth wave. In Uganda, this corresponded to 92 in the first
- wave, 422 in the second wave and 65 in the third wave (Table 3).
- 271 There was an increase in seropositivity with each subsequent wave, and the majority (70-
- 100%) of women with positive serology were asymptomatic in the 14 days prior to sampling.
- 273 Fig 2 shows the monthly total antibody positivity rate for each site with the daily number of
- 274 new cases per million in Uganda and Malawi. The concordance between maternal and cord
- 275 samples was high (72-99%).
- 276

Fig 2. Monthly sero-positivity by country in pregnant women. Black line is the monthly
proportion of results that were positive. Shaded in green is the proportion of Wantai
positive samples that were also positive for anti-spike IgG in the Euroimmune assay. Blue
line is the number of new cases per million in Malawi and Uganda, taken from Our World in
Data.

- 282
- 283
- 284
- 285

#### 286 Table 3 – Maternal results

	PeriCOVID Malawi			PeriCOVIE	) Uganda	COMAC Uganda	
Characteristic	Wave 2, N = 51 N (%) (95% Cl)	Wave 3, N = 229 N (%) (95% CI)	Wave 4, N = 107 N (%) (95% Cl)	Wave 1, N = 194 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% Cl)	Wave 3, N = 74 N (%) (95% Cl)
Maternal blood sa	ample						
Negative	24 (51%) (36%, 66%)	75 (33%) (27%, 39%)	26 (24%) (17%, 34%)	102 (53%) (45%, 60%)	240 (38%) (34%, 41%)	22 (27%) (18%, 38%)	7 (9.6%) (3.9%, 19%)
Positive	23 (49%) (34%, 64%)	153 (67%) (61%, 73%)	81 (76%) (66%, 83%)	92 (47%) (40%, 55%)	400 (62%) (59%, 66%)	60 (73%) (62%, 82%)	66 (90%) (81%, 96%)
Missing	4	1	0	0	2	0	1
Symptoms in thos	se seropositive						
Asymptomatic	21 (91%) (72%, 99%)	134 (88%) (81%, 92%)	57 (70%) (59%, 80%)	92 (100%) (96%, 100%)	362 (91%) (87%, 93%)	60 (100%) (94%, 100%)	65 (98%) (92%, 100%)
Symptomatic	2 (8.7%) (1.1%, 28%)	19 (12%) (7.6%, 19%)	24 (30%) (20%, 41%)	0 (0%) (0.00%, 3.9%)	38 (9.5%) (6.8%, 13%)	0 (0%) (0.00%, 6.0%)	1 (1.5%) (0.04%, 8.2%)
Symptoms in thos	se seronegative				1	1	
Asymptomatic	24 (100%) (86%, 100%)	61 (81%) (71%, 89%)	12 (46%) (27%, 67%)	101 (99%) (95%, 100%)	223 (93%) (89%, 96%)	22 (100%) (85%, 100%)	7 (100%) (59%, 100%)

	Р	eriCOVID Malawi		PeriCOVID Uganda		COMAC Uganda	
Characteristic	Wave 2, N = 51 N (%) (95% Cl)	Wave 3, N = 229 N (%) (95% CI)	Wave 4, N = 107 N (%) (95% Cl)	Wave 1, N = 194 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% Cl)	Wave 2, N = 82 N (%) (95% Cl)	Wave 3, N = 74 N (%) (95% Cl)
Symptomatic	0 (0%) (0.00%, 14%)	14 (19%) (11%, 29%)	14 (54%) (33%, 73%)	1 (1.0%) (0.02%, 5.3%)	17 (7.1%) (4.2%, 11%)		

#### 288 Table 4 – Cord blood serology

	PeriCOVID Malawi		PeriCOVID Uganda		COMAC Uganda		
Characteristic	Wave 2, N = 52 N (%) (95% Cl)	Wave 3, N = 230 N (%) (95% CI)	Wave 4, N = 111 N (%) (95% CI)	Wave 1, N = 195 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% Cl)	Wave 3, N = 74 N (%) (95% Cl)
Concordance of	maternal and cord	blood samples					
Concordant	35 (80%) (65%, 90%)	194 (92%) (88%, 96%)	101 (96%) (91%, 99%)	79 (82%) (73%, 89%)	271 (72%) (67%, 76%)	81 (99%) (93%, 100%)	68 (96%) (88%, 99%)
Discordant	9 (20%) (9.8%, 35%)	16 (7.6%) (4.4%, 12%)	4 (3.8%) (1.0%, 9.5%)	17 (18%) (11%, 27%)	106 (28%) (24%, 33%)	1 (1.2%) (0.03%, 6.6%)	3 (4.2%) (0.88%, 12%)
Missing	8	20	6	99	265	0	3
Cord blood resu	lts with positive ma	ternal blood resul	lt	l	I	I	I
Negative	8 (40%) (19%, 64%)	14 (10%) (5.7%, 17%)	3 (3.8%) (0.78%, 11%)	8 (18%) (8.2%, 33%)	38 (16%) (12%, 21%)	0 (0%) (0.00%, 6.0%)	3 (4.7%) (0.98%, 13%)
Positive	12 (60%) (36%, 81%)	123 (90%) (83%, 94%)	77 (96%) (89%, 99%)	36 (82%) (67%, 92%)	198 (84%) (79%, 88%)	60 (100%) (94%, 100%)	61 (95%) (87%) 99%)
Missing	3	15	3	48	165	0	2
Cord blood resu	lt with negative ma	ternal blood resul	t	1	1	1	1
Negative	23 (96%) (79%, 100%)	71 (97%) (90%, 100%)	24 (96%) (80%, 100%)	43 (83%) (70%, 92%)	73 (52%) (43%, 60%)	21 (95%) (77%, 100%)	7 (100%) (59%) 100%)

	PeriCOVID Malawi			PeriCOVID Uganda		COMAC Uganda	
Characteristic	Wave 2, N = 52 N (%) (95% Cl)	Wave 3, N = 230 N (%) (95% CI)	Wave 4, N = 111 N (%) (95% CI)	Wave 1, N = 195 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% Cl)	Wave 3, N = 74 N (%) (95% Cl)
Positive	1 (4.2%) (0.11%, 21%)	2 (2.7%) (0.33%, 9.5%)	1 (4.0%) (0.10%, 20%)	8 (15%) (6.9%, 28%)	68 (48%) (40%, 57%)	1 (4.5%) (0.12%, 23%)	0 (0%) (0.00%, 41%)
Missing	1	4	3	52*	98		

289 \* 1 cord blood sample in PeriCOVID Uganda was insufficient for analysis

290

#### 291 SARS-CoV-2 infection in pregnancy and key adverse pregnancy and

### 292 neonatal outcomes

- 1220/1224 mothers had serology results at enrolment available for analysis and were
- included in the analysis of Sars-CoV-2 infection and pregnancy outcomes. 79/1220 mothers
- experienced at least one adverse pregnancy outcome (maternal death N=4, abortion N=4,
- premature labour N=52, and stillbirth N=26) and there were 46 infant deaths (Supp Table 4
- and 5). Of the 79 adverse pregnancy outcomes, 34 (43%) mothers were sero-negative, and
- 45 (57%) mothers were sero-positive, compared to 435 (38%) mothers who were sero-
- negative and 706 (62%) mothers who were sero-positive with no adverse pregnancy
- 300 outcomes. There was no difference in pregnancy outcomes due to sero-positive SARS-CoV-
- 301 2 status (Table 5). Due to the small numbers of outcomes, the impact of Sars-CoV-2
- 302 infection on maternal death could not be modelled. There was also no difference in
- 303 outcomes due to SARS-CoV-2 infection with and without symptoms in the 14 days
- 304 (periCOVID Uganda and Malawi) -28 days (COMAC) prior to enrolment (Supp Table 6).

	Number included in model	Number of events	<b>Relative Risk</b>	95% Confidence Interval
Maternal death			·	
Sero-Negative		1	—	—
Sero-Positive		3	—	—
Infant death				
Sero-Negative	471	20	—	—
Sero-Positive	752	26	0.81	0.46, 1.46
Premature labour				
Sero-Negative	476	20	—	—
Sero-Positive	758	32	0.97	0.57, 1.71
Still birth		·		
Sero-Negative	473	15	—	—
Sero-Positive	752	11	0.48	0.22, 1.03
Abortion		·		
Sero-Negative		0	—	-
Sero-Positive		4	—	—
Combined adverse pregnancy outcome				
Sero-Negative	463	34	—	—
Sero-Positive	742	45	0.81	0.53, 1.26
Low birth weight				
Sero-Negative	474	22	—	—
Sero-Positive	753	39	0.98	0.60, 1.65
NICU admission				
Sero-Negative	471	63	_	_

306 Table 5– Impact of infection (seropositivity) on key pregnancy and neonatal outcomes in Pericovid Malawi and Pericovid Uganda

Sero-Positive	753	107	0.96	0.73, 1.28
Combined adverse neonatal outcome				
Sero-Negative	476	77	—	—
Sero-Positive	758	120	0.92	0.71, 1.19

307 Models are adjusted for country

There were 197 adverse infant outcomes (at least one of: infant/neonatal death, 308 prematurity, low birth weight, NICU admission and birth asphyxia). There were 46 infant 309 deaths, 26 (57%) from sero-positive and 20 (43%) from sero-negative women (Supp Table 310 5). There was no difference in risk of infant death due to SARS-CoV-2 serology status in the 311 mother (Table 5). 77 (39%) infants with adverse outcomes were born to women who were 312 sero-negative and 120 (61%) sero-positive. The relative risk was 0.92 (95% CI 0.71, 1.19), 313 providing no evidence of a difference in the risk of at least one adverse neonatal outcome 314 due to serological status of the mother. There was also no evidence of a difference in 315 316 neonatal outcome due to positive serological status with and without symptoms in the mother (Supp Tables 4 and 5). 317

318

### <sup>319</sup> Placental transfer of SARS-CoV-2 antibodies in those with prior

### 320 infection and/or vaccination

321 In PeriCOVID Uganda, 208/503 mother-infant pairs had anti-S IgG results available for

analysis, corresponding to 27 and 181 during the first and second waves respectively. There

323 was no difference between the maternal and cord blood anti-S IgG GMCs during the first

wave. The GMR in the second wave was 1.7 (1.3, 2.3), indicating that anti-S IgG was higher

in the cord blood than the maternal blood at enrolment. In comparison, in COMAC Uganda

the GMR indicated no difference between the maternal and cord blood anti-S IgG for the 60

327 mother-infant pairs enrolled during the second wave, or for the 59 enrolled during the third

wave (Supp Table 7). The rate of placental transfer of anti-S IgG is plotted in Fig 3.

329

#### Fig 3. Placental transfer of anti-s IgG in A) PeriCOVID Uganda and B) COMAC Uganda.

331 Geometric mean ratios (GMRs) of anti-spike IgG for each mother-infant pair with results

available for analysis on the Euroimmune anti-spike IgG assay. Boxplots of the GMRs show

no evidence of a difference in placental transfer in different waves of the pandemic.

334

There were 39 mother-infant pairs enrolled in PeriCOVID Uganda during the first wave with anti-NCP results, and 194 during the second wave. For both waves, there was no evidence

337	of a difference in the maternal and cord blood anti-NCP IgG results. In COMAC Uganda, 55
338	and 43 mother-infant pairs enrolled during the second and third waves, respectively, had
339	anti-NCP IgG results. The GMR in the second wave was 1.8 (1.1, 2.9), and in the third wave
340	was 2.7 (1.7, 4.4), indicating that anti-NCP IgG was higher in cord blood samples than in the
341	maternal blood (Supp Table 7). The rate of placental transfer of anti-NCP IgG is plotted in
342	Fig 3 . There was no clear evidence of a difference in placental transfer of both anti-S and
343	anti-NCP IgG during different waves (Fig 3 and Fig S1).

344

### 345 Number of vaccinated women during pregnancy

A total of 29 participants across all sites reported prior vaccination to SARS-CoV-2: 7 from

347 Malawi, 1 from periCOVID Uganda and 21 from COMAC. Monthly numbers of positive

results in COMAC Uganda by vaccination status can be seen in Fig S2.

349

## 350 **Discussion**

This study describes the increasing prevalence of SARS CoV-2 infection across 2 countries and 5 hospital sites in East and southern Africa, and across several COVID-19 waves. This increase in prevalence coincided with waves of delta and omicron infection within the countries, respectively. Our data indicates that the majority of cases were asymptomatic and adds to existing evidence that suggests under-reporting of infection if based solely on confirmed cases by PCR(4, 5, 21).

357

358 The high prevalence of poor maternal and child health outcomes in sub-Saharan Africa,

359 combined with the known impact of SARS-CoV-2 illness in pregnancy from existing studies

360	outside of Africa (22-26), means that we need to better understand the direct effects of
361	exposure to COVID-19 in pregnancy and outcome for the pregnant woman and her infant.
362	The INTERCOVID study (27), which included 2 sites in West Africa (Nigeria and Ghana)
363	showed that infection in pregnancy was associated with increased maternal and neonatal
364	morbidity and mortality. The AFREHEALTH study of 1315 hospitalized pregnant and non-
365	pregnant women with and without SARS-CoV-2 revealed an increased risk of ICU admission
366	and in-hospital death amongst pregnant women with COVID-19 (28). Though we are unable
367	to assess outcomes for symptomatic SARS-CoV-2 illness in our cohort due to low numbers
368	our study does highlight that asymptomatic infection does not appear to be associated with
369	death in the mother, or with worse neonatal outcomes in the first month of life. This is
370	reassuring to parents and health care providers. Furthermore, in our study placental
371	transfer of IgG increased during each subsequent wave. Previous studies earlier in the
372	pandemic suggested reduced placental transfer of IgG in women with a positive SARS-CoV-2
373	RT-PCR (29, 30). More research is needed to better understand placental transfer with
374	different SARS-CoV-2 variants.

375

#### 376 Limitations

Our study is limited by differences in methodology across sites, with sampling performed at different time points in pregnancy, despite efforts to adhere to the UNITY protocol. The uniform collection of cord blood across all sites however enables comparison across sites and strengthens our results. In PeriCOVID Uganda, a strict period of lockdown over the summer of 2021 with a ban on public transport made it challenging for participants to attend hospital for delivery, leading to a lower number of cord blood samples than

anticipated. Calls to participants by healthcare visitors were increased to ensure that 383 women were aware that study staff were still working and could care for them during their 384 delivery. We report our primary outcomes using the Wantai assay, but for placental 385 antibody transfer, we report IgG using Euroimmune results. However, we identified cross-386 387 reactivity of antibodies against *Plasmodium falciparum* or other common cold coronaviruses (CCCs) as has been reported elsewhere in East Africa (21), meaning these results should be 388 reviewed with caution. We had initially planned to use the Euroimmune anti-NCP assay to 389 390 differentiate between infection and vaccination. However, the specificity of the assay precluded its use for this purpose. The Euroimmune anti-NCP assay has a lower sensitivity 391 than other assays (31). Several studies have shown a low anti-NCP positivity after mild 392 infections (32). As the pandemic progressed the chance of repeat SARS-CoV-2 infection 393 394 increased, though these infections were generally milder (32). Anti-NCP antibodies in some 395 studies have remained negative in individuals who were vaccinated against SARS-CoV-2 and who had an rt-PCR confirmed illness (32). A lower anti-NCP seropositivity later in the 396 pandemic may therefore represent assay sensitivity and a lower anti-NCP immune response 397 following mild or asymptomatic infection. 398

399

## 400 Conclusion

401 Data from Uganda and Malawi showed a seroprevalence of SARS-CoV-2 higher than the

402 cases figures identified by other sources. In future pandemics and outbreaks,

403 seroprevalence studies may be a more accurate measure in assessing the true prevalence of404 infection.

#### 405

# 406 Acknowledgments

- 407 The periCOVID Consortium consists of:
- 408 Esperança Sevene<sup>1,2</sup>, Sónia Maculuve<sup>1</sup>, Anifa Valá<sup>1</sup>, Angela Koech<sup>3</sup>, Geoffrey Omuse<sup>4</sup>,
- 409 Marleen Temmerman<sup>3</sup>

410	1.	Manhiça Health Research Center, Manhiça, Mozambique
411	2.	Department of Physiological Science, Faculty of Medicine, Eduardo Mondlane University,
412		Maputo, Mozambique
413	3.	Centre of Excellence in Women and Child Health, Aga Khan University, Kenya
414	4.	Department of Pathology, Aga Khan University, Kenya
415		
416		
417		
418	We wo	ould also like to thank all study and laboratory staff who enabled recruitment, follow-
419	up, an	d study testing.

420

## 422 **References**

- 423 1. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong
- JN. COVID-19 in Africa: the spread and response. Nature Medicine. 2020;26(7):999-1003.

425 2. Abatan B, Agboghoroma O, Akemoke F, Antonio M, Awokola B, Bittaye M, et al.

426 Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia. Emerging

427 infectious diseases. 2021;27(8):2064.

428 3. Martinez-Alvarez M, Jarde A, Usuf E, Brotherton H, Bittaye M, Samateh AL, et al.

429 COVID-19 pandemic in west Africa. The lancet global health. 2020;8(5):e631-e2.

430 4. Adams J, MacKenzie MJ, Amegah AK, Ezeh A, Gadanya MA, Omigbodun A, et al.

431 The conundrum of low COVID-19 mortality burden in sub-Saharan Africa: myth or reality?

432 Global Health: Science and Practice. 2021;9(3):433-43.

433 5. Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et al.

434 COVID-19 pandemic: is Africa different? Journal of the National Medical Association.

435 2021;113(3):324-35.

6. Norton A, Gozalo ADLH, De Colombi NF, Alobo M, Asego JM, Al-Rawni Z, et al.
The remaining unknowns: a mixed methods study of the current and global health research
priorities for COVID-19. BMJ Global Health. 2020;5(7):e003306.

Tsinda EK, Mmbando GS. Recent updates on the possible reasons for the low
incidence and morbidity of COVID-19 cases in Africa. Bulletin of the National Research
Centre. 2021;45(1):1-8.

8. Sié A, Hanefeld J, Chaponda M, Chico RM, LeDoare K, Mayaud P, et al. Congenital
malformations in sub-Saharan Africa—warnings of a silent epidemic? The Lancet Infectious
Diseases. 2021;21(5):594-6.

445 9. Shah AV, Howell HB, Kazmi SH, Zaccario M, Sklamberg FE, Groth T, et al.

- 446 Developmental screening of full-term infants at 16 to 18 months of age after in-utero
- exposure to maternal SARS-CoV-2 infection. Journal of Perinatology. 2023;43(5):659-63.
- 10. Edlow AG, Castro VM, Shook LL, Haneuse S, Kaimal AJ, Perlis RH. Sex-Specific
- 449 Neurodevelopmental Outcomes Among Offspring of Mothers With SARS-CoV-2 Infection
- 450 During Pregnancy. JAMA Network Open. 2023;6(3):e234415-e.
- 451 11. Emily RS, Erin O, Gargi Wable G, Kacey F, Fouzia F, Yalda A, et al. Adverse
- 452 maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection:
- an individual participant data meta-analysis. BMJ Global Health. 2023;8(1):e009495.
- 454 12. Wilson SE, Deeks SL, Hatchette TF, Crowcroft NS. The role of seroepidemiology in
- the comprehensive surveillance of vaccine-preventable diseases. Cmaj. 2012;184(1):E70-E6.
- 456 13. Lai C-C, Wang J-H, Hsueh P-R. Population-based seroprevalence surveys of anti-
- 457 SARS-CoV-2 antibody: An up-to-date review. International Journal of Infectious Diseases.
- 458 2020;101:314-22.
- 459 14. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al.
- 460 High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of
- deaths in urban Malawi. medrxiv. 2020.
- 462 15. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al.
- 463 Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape
- 464 Town, South Africa. PLoS One. 2021;16(2):e0247852.
- 16. Uyoga S, Adetifa IM, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al.
- 466 Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science.
- 467 2021;371(6524):79-82.

- 468 17. WHO. Generic protocol: a prospective cohort study investigating maternal, pregnancy
- 469 and neonatal outcomes for women and neonates infected with SARS-CoV-2. Geneva World
- 470 Health Organisation 2020
- 471 18. WHO. WHO COVID-19 Case definition
- 472 2020 [Available from: <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-</u>
- 473 <u>Surveillance Case Definition-2020.2</u>.
- 474 19. FIND DFA. FIND EVALUATION OF SARS-COV-2 ANTIBODY (AB)
- 475 DETECTION TESTS 2021 [cited 2022 April 21st ]. Available from:
- 476 <u>https://www.finddx.org/sarscov2-eval-antibody/</u>.
- 477 20. Edouard Mathieu HR, Lucas Rodés-Guirao, Cameron Appel, Daniel Gavrilov,
- 478 Charlie Giattino, Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban
- 479 Ortiz-Ospina, and Max Roser. Coronavirus Pandemic (COVID-19) 2023 [Available from:
- 480 <u>https://ourworldindata.org/coronavirus#coronavirus-country-profiles</u>.
- 481 21. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection
- 482 in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from
- 483 January 2020 to December 2021. BMJ Global Health. 2022;7(8):e008793.
- 484 22. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:
- 485 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed
- 486 SARS-CoV-2 Infection by Pregnancy Status United States, January 22-October 3, 2020.
- 487 MMWR Morb Mortal Wkly Rep. 2020;69(44):1641-7.
- 488 23. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are
- 489 clinical outcomes worse for pregnant women at  $\geq 20$  weeks' gestation infected with
- 490 coronavirus disease 2019? A multicenter case-control study with propensity score matching.
- 491 Am J Obstet Gynecol. 2020;223(5):764-8.

492 24. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical

- 493 manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019
- in pregnancy: living systematic review and meta-analysis. Bmj. 2020;370:m3320.
- 495 25. Budhram S, Vannevel V, Botha T, Chauke L, Bhoora S, Balie GM, et al. Maternal
- 496 characteristics and pregnancy outcomes of hospitalized pregnant women with SARS-CoV-2
- 497 infection in South Africa: An International Network of Obstetric Survey Systems-based
- 498 cohort study. Int J Gynaecol Obstet. 2021;155(3):455-65.
- 499 26. De Waard L, Langenegger E, Erasmus K, Van der Merwe T, Olivier SE, Du Toit N,
- 500 et al. Maternal and neonatal outcomes of COVID-19 in a high-risk pregnant cohort with and
- 501 without HIV. S Afr Med J. 2021;111(12):1174-80.
- 502 27. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal
- and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-
- 504 19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatrics.
- 505 2021;175(8):817-26.
- 506 28. Nachega JB, Sam-Agudu NA, Machekano RN, Rosenthal PJ, Schell S, de Waard L, et
- al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Pregnancy in Sub-
- 508 Saharan Africa: A 6-Country Retrospective Cohort Analysis. Clinical Infectious Diseases.
- 509 2022;75(11):1950-61.
- 510 29. Rubio R, Aguilar R, Bustamante M, Muñoz E, Vázquez-Santiago M, Santano R, et al.
- 511 Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and
- 512 cytokine profile. Front Immunol. 2022;13:999136.
- 513 30. Edlow AG, Li JZ, Collier A-rY, Atyeo C, James KE, Boatin AA, et al. Assessment of
- 514 Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and
- 515 Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Network Open.
- 516 2020;3(12):e2030455-e.

- 517 31. Otter A. Personal Communication 2023
- 518 32. Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, et al.
- 519 Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the
- 520 Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
- 521 Ann Intern Med. 2022;175(9):1258-65.
- 522

# **Supplementary Information**

**S1 Fig. Placental transfer of anti-n IgG in A) PeriCOVID Uganda and B) COMAC Uganda**. Geometric mean ratios (GMRs) of anti-nucelocapsid IgG for each mother-infant pair with results available for analysis on the Euroimmune anti-nucleocapsid IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic

**S2 Fig. Monthly number of positives in COMAC Uganda, by vaccination status** The monthly number of women in COMAC Uganda who were seropositive at enrolment on each of the Wantai (top panel), Euroimmune anti-S (middle panel) and Euroimmune anti-N (bottom panel) assays, coloured by vaccination status. Green shows those who were unvaccinated at enrolment, blue shows the small proportion who were vaccinated, and red shows those whose vaccination status was unknown at enrolment. The majority were unvaccinated.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.19.23294311; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

#### 523

### 524 S1 Table. Wantai Assay Specificity.

	Wantai positive (n)	Wantai negative (n)	Specificity (%)
2019 samples, malaria	1	73	98.65
positive (n=74)			
2019 samples, malaria	1	99	99
negative (n=100)			

525

#### 526 S2 Table. Dates used to define COVID-19 waves in Malawi and Uganda

Country	Wave 1	Wave 2	Wave 3	Wave 4
Uganda	26/03/2020 -	22/03/2021 -	01/12/2021 -	
	21/03/2021	30/11/2021	30/04/2022	
Malawi	07/04/2020 -	17/11/2020 -	16/05/2021 -	12/11/2021 -
	16/11/2020	15/05/2021	11/11/2021	20/04/2022

### 528 S3 Table – Maternal PCR tests by study site and wave

	PeriCOVID Malawi				PeriCOVID Uganda		
Characteristic	Overall, N = 73 (95% Cl) <sup>12</sup>	Wave 2, N = 2 (95% Cl) <sup>12</sup>	Wave 3, N = 31 (95% Cl) <sup>12</sup>	Wave 4, N = 40 (95% CI) <sup>12</sup>	Overall, N = 836 (95% Cl) <sup>12</sup>	Wave 1, N = 194 (95% Cl) <sup>12</sup>	Wave 2, N = 642 (95% CI) <sup>12</sup>
PCR result							
Negative	24 (33%) (22%, 45%)	1 (50%) (1.3%, 99%)	11 (35%) (19%, 55%)	12 (30%) (17%, 47%)	817 (98%) (96%, 99%)	194 (100%) (98%, 100%)	623 (97%) (95%, 98%)
Positive	49 (67%) (55%, 78%)	1 (50%) (1.3%, 99%)	20 (65%) (45%, 81%)	28 (70%) (53%, 83%)	19 (2.3%) (1.4%, 3.5%)	0 (0%) (0.00%, 1.9%)	19 (3.0%) (1.8%, 4.6%)
Symptoms in those with positive PCR							
Asymptomatic	2 (4.1%) (0.50%, 14%)	0 (0%) (0.00%, 98%)	0 (0%) (0.00%, 17%)	2 (7.1%) (0.88%, 24%)	13 (68%) (43%, 87%)	NA	13 (68%) (43%, 87%)
Symptomatic	47 (96%) (86%, 100%)	1 (100%) (2.5%, 100%)	20 (100%) (83%, 100%)	26 (93%) (76%, 99%)	6 (32%) (13%, 57%)	NA	6 (32%) (13%, 57%)

529 Symptoms are those defined as probable infection according to WHO criteria (18)

537 S4 Table – Adverse pregnancy outcomes in mothers enrolled in PeriCOVID Malawi and PeriCOVID Uganda

	All Enrolled	Wantai Overall	Wantai Serostatus		
Characteristic	N = 1,224 <sup>1</sup>	N = 1,220 <sup>1</sup>	Negative, N = 469 <sup>2</sup>	Positive, N = 751 <sup>2</sup>	
Maternal death	4 (0.3%)	4 (0.3%)	1 (25%)	3 (75%)	
Unknown	27	25	9	16	
Abortion	4 (0.3%)	4 (0.3%)	0 (0%)	4 (100%)	
Unknown	25	24	9	15	
Premature labour	52 (4.3%)	52 (4.3%)	20 (38%)	32 (62%)	
Unknown	1				
Stillbirth	26 (2.1%)	26 (2.1%)	15 (58%)	11 (42%)	
At least one adverse pregnancy outcome	79 (6.5%)	79 (6.5%)	34 (43%)	45 (57%)	
No adverse pregnancy outcome	1,145 (94%)	1,141 (94%)	435 (38%)	706 (62%)	
Livebirth	1,198 (98%)	1,194 (98%)	454 (38%)	740 (62%)	

<sup>1</sup> Column percentages are presented for the overall number of women experiencing each outcome

<sup>2</sup> Row percentages are presented for the number of seropositive and seronegative women experiencing each outcome

#### **S5 Table - Adverse neonatal outcomes in infants born in PeriCOVID Malawi and PeriCOVID Uganda**

	All infants Wantai Overall Maternal Wantai Serostatus		S	
Characteristic	N = 1,230 <sup>1</sup>	N = 1,227 <sup>1</sup>	Negative, N = 474 <sup>2</sup>	Positive, N = 753 <sup>2</sup>
Infant death	46 (3.8%)	46 (3.8%)	20 (43%)	26 (57%)
Unknown	5	4	3	1
Prematurity	58 (4.7%)	58 (4.7%)	22 (38%)	36 (62%)
Unknown	1			
Low birth weight	61 (5.0%)	61 (5.0%)	22 (36%)	39 (64%)
Unknown	1			
Admitted to NICU	170 (14%)	170 (14%)	63 (37%)	107 (63%)
Unknown	4	3	3	0
Birth asphyxia	53 (4.3%)	53 (4.3%)	20 (38%)	33 (62%)
Unknown	1			
At least one adverse neonatal outcome	197 (16%)	197 (16%)	77 (39%)	120 (61%)
No adverse neonatal/infant outcome	1,033 (84%)	1,030 (84%)	397 (39%)	633 (61%)

<sup>1</sup> Column percentages are presented for the overall number of infants experiencing each outcome

<sup>2</sup> Row percentages are presented for the number of infants born to seropositive and seronegative women with each outcome

551 S6 Table - Impact of infection (seropositive and WHO probable) on key pregnancy and neonatal outcomes

	Number included in model	Number of events	Relative Risk	95% Confidence Interval
Maternal death				
Infection status		4		
sero-negative		1	—	—
sero-positive and not WHO probable		0	-	_
sero-positive and WHO probable		3	—	_
Infant death			,	
Infection status	1,223	46		
sero-negative	471	20	-	—
sero-positive and not WHO probable	667	24	0.85	0.47, 1.53
sero-positive and WHO probable	85	2	—	—
Premature labour			·	
Infection status	1,234	52		
Sero- negative	476	20	-	—
Sero- positive and not WHO probable	672	27	0.94	0.53, 1.67
Sero- positive and WHO probable	86	5	1.24	0.42, 3.00
Still birth				
Infection status	1,225	26		
Sero- negative	473	15	-	—
Sero- positive and not WHO probable	667	10	0.48	0.21, 1.05
Sero- positive and WHO probable	85	1	-	—
Abortion			·	
Infection status		4		
Sero- negative		0	-	—
Sero- positive and not WHO probable		4	_	_
Sero- positive and WHO probable		0	-	

Combined adverse pregnancy outcome				
Infection status	1,205	79		
Sero- negative	463	34	—	—
Sero- positive and not WHO probable	659	36	0.74	0.47, 1.16
Sero- positive and WHO probable	83	9	1.39	0.64, 2.68
Low birth weight		·		
Infection status	1,227	61		
Sero- negative	474	22	—	—
Sero- positive and not WHO probable	668	33	0.99	0.59, 1.67
Sero- positive and WHO probable	85	6	0.98	0.37, 2.17
NICU admission		·	·	
Infection status	1,224	170		
Sero- negative	471	63	—	-
Sero- positive and not WHO probable	668	90	0.95	0.72, 1.28
Sero- positive and WHO probable	85	17	1.03	0.62, 1.60
Combined adverse neonatal outcome	·	·	·	
Infection status	1,234	197		
Sero- negative	476	77	-	—
Sero- positive and not WHO probable	672	102	0.91	0.70, 1.19
Sero- positive and WHO probable	86	18	0.98	0.60, 1.50

552 Models are adjusted for country


### 553 S7 Table - Placental Transfer

		PeriCOVID Uganda		COMAC Uganda	
		Wave 1	Wave 2	Wave 2	Wave 3
Anti-S	Infant, GMC (95% CI)	78.8 (46.4, 133.7) [N = 27]	127.6 (100.6, 161.8) [N = 181]	152 (100.3, 230.3) [N = 60]	65.2 (47.1, 90.4) [N = 59]
	Mother, GMC (95% CI)	51.7 (34.6, 77.3) [N = 27]	74.7 (59.3, 94.2) [N = 181]	96.1 (65.9, 140.1) [N = 60]	98.5 (68.6, 141.5) [N = 59]
	Placental transfer, GMR (95% CI)	1.5 (0.9, 2.5) [N = 27]	1.7 (1.3, 2.3) [N = 181]	1.6 (0.8, 3) [N = 60]	0.7 (0.4, 1) [N = 59]
Anti-N	Infant, GMC (95% CI)	57.1 (38, 85.8) [N = 39]	133.7 (106.5, 167.8) [N = 194]	155.9 (102.1, 237.9) [N = 55]	172 (103, 287.2) [N = 43]
	Mother, GMC (95% CI)	57.6 (41.5, 79.9) [N = 39]	146.2 (114.4, 186.8) [N = 194]	87.6 (54.9, 139.8) [N = 55]	62.9 (35.5, 111.4) [N = 43]
	Placental transfer, GMR (95% CI)	1 (0.6, 1.6) [N = 39]	0.9 (0.7, 1.3) [N = 194]	1.8 (1.1, 2.9) [N = 55]	2.7 (1.7, 4.4) [N = 43]

medRxiv preprint doi: https://doi.org/10.1101/2023.08.19.23294311; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.19.23294311; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

### Figure 1 - Study flow chart



Study flow chart to show the number of women enrolled by study, with maternal serology available at enrolment (maternal result) and the infants with cord blood serology (cord blood result) available

# Figure 1




Figure 2 - Monthly sero-positivity by country in pregnant women

# Figure 2




Figure 3 - Placental transfer of anti-s IgG in A) PeriCOVID Uganda and B) COMAC Uganda

Geometric mean ratios (GMRs) of anti-spike IgG for each mother-infant pair with results available for analysis on the Euroimmune anti-spike IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic.

# Figure 3




Figure S1 - Placental transfer of anti-n IgG in A) PeriCOVID Uganda and B) COMAC Uganda

Geometric mean ratios (GMRs) of anti-nucelocapsid IgG for each mother-infant pair with results available for analysis on the Euroimmune antinucleocapsid IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic

# Supp Figure 1




Figure S2 - Monthly number of positives in COMAC Uganda, by vaccination status

The monthly number of women in COMAC Uganda who were seropositive at enrolment on each of the Wantai (top panel), Euroimmune anti-S (middle panel) and Euroimmune anti-N (bottom panel) assays, coloured by vaccination status. Green shows those who were unvaccinated at enrolment, blue shows the small proportion who were vaccinated, and red shows those whose vaccination status was unknown at enrolment. The majority were unvaccinated.

### Supp Figure 2